BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 12834116)

  • 21. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
    Casserly P; Timon C
    J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
    Meyer TK; Hu A; Hillel AD
    Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laryngeal dystonia: case report and treatment with botulinum toxin.
    Santos VJ; Mattioli FM; Mattioli WM; Daniel RJ; Cruz VP
    Braz J Otorhinolaryngol; 2006; 72(3):425-7. PubMed ID: 17119783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
    Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
    J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia.
    Epstein R; Stygall J; Newman S
    Disabil Rehabil; 1997 Jan; 19(1):20-5. PubMed ID: 9021281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
    Nerurkar NK; Banu TP
    J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
    Kang MS; Lee SJ; Choi HS; Lim JY
    Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Whurr R; Lorch M; Fontana H; Brookes G; Lees A; Marsden CD
    J Neurol Neurosurg Psychiatry; 1993 May; 56(5):526-30. PubMed ID: 8505645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia.
    Lundy DS; Lu FL; Casiano RR; Xue JW
    J Voice; 1998 Dec; 12(4):460-6. PubMed ID: 9988033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of repeated botulinum toxin injections as a function of timing.
    Inagi K; Ford CN; Rodriquez AA; Schultz E; Bless DM; Heisey DM
    Ann Otol Rhinol Laryngol; 1997 Dec; 106(12):1012-9. PubMed ID: 9415596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin.
    Esposito M; Dubbioso R; Apisa P; Allocca R; Santoro L; Cesari U
    Neurol Sci; 2015 Sep; 36(9):1679-82. PubMed ID: 25966878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
    Namin AW; Christopher KM; Eisenbeis JF
    J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional reinnervation of vocal folds after selective laryngeal adductor denervation-reinnervation surgery for spasmodic dysphonia.
    DeConde AS; Long JL; Armin BB; Berke GS
    J Voice; 2012 Sep; 26(5):602-3. PubMed ID: 22516313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
    Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
    J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
    Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
    J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
    Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
    Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
    Mendelsohn AH; Berke GS
    Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.